Tick-borne encephalitis virus seroprevalence and infection
incidence in Switzerland, 2020-2021

J 2025

Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021

BRECHET, Arthur; Philipp KOHLER; Tamara DORR; Fabian GRASSLI; Michael VOCK et al.

Základní údaje

Originální název

Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021

Autoři

Vydání

Scientific Reports, Berlin, Nature Research, 2025, 2045-2322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10606 Microbiology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/25:00142754

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Tick-borne encephalitis; TBE; TBEV; Orthoflavivirus; Prevalence; Incidence; Asymptomatic; Abortive

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 12. 2025 10:13, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconversions in unvaccinated individuals were confirmed by seroneutralization testing. Questionnaire data were used to determine vaccination status and risk factors. TBEV E protein-specific IgG prevalence was 72.1% (95% CI 68.2–75.7%) in TBEV-vaccinated and 6% (95% CI 4.4–7.8%) in unvaccinated individuals. The estimated annual incidence of infection was 735/100,000. Age was the only factor significantly associated with seroprevalence. The seroreversion rate in unvaccinated individuals was 30.3% within one year, which is almost ten times higher than in vaccinated individuals (3.4%, annual decline rate 8.0%). NS1-specific IgG antibodies were six times more common in vaccinated than unvaccinated HCWs. In conclusion, undetected TBEV infections are common, and infection incidence is much higher than reported clinical cases. Individuals with abortive infections have high antibody decline and seroreversion rates. Whether lifelong protection is conferred and by which immune subsets remain unclear.

Citovat

BRECHET, Arthur; Philipp KOHLER; Tamara DORR; Fabian GRASSLI; Michael VOCK; Jiří SALÁT; Daniel RŮŽEK; Andree FRIEDL; Danielle VUICHARD-GYSIN; Antony CROXATTO; Reto LIENHARD a Rahel ACKERMANN-GAUMANN. Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021. Scientific Reports. Berlin: Nature Research, 2025, roč. 15, č. 1, s. 8346-8358. ISSN 2045-2322. Dostupné z: https://doi.org/10.1038/s41598-025-92560-1.

@article{2536906,
   author = {Brechet, Arthur and Kohler, Philipp and Dorr, Tamara and Grassli, Fabian and Vock, Michael and Salát, Jiří and Růžek, Daniel and Friedl, Andree and VuichardandGysin, Danielle and Croxatto, Antony and Lienhard, Reto and AckermannandGaumann, Rahel},
   article_location = {Berlin},
   article_number = {1},
   doi = {https://doi.org/10.1038/s41598-025-92560-1},
   keywords = {Tick-borne encephalitis; TBE; TBEV; Orthoflavivirus; Prevalence; Incidence; Asymptomatic; Abortive},
   language = {eng},
   issn = {2045-2322},
   journal = {Scientific Reports},
   title = {Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021},
   url = {https://www.nature.com/articles/s41598-025-92560-1},
   volume = {15},
   year = {2025}
}

TY  - JOUR
ID  - 2536906
AU  - Brechet, Arthur - Kohler, Philipp - Dorr, Tamara - Grassli, Fabian - Vock, Michael - Salát, Jiří - Růžek, Daniel - Friedl, Andree - Vuichard-Gysin, Danielle - Croxatto, Antony - Lienhard, Reto - Ackermann-Gaumann, Rahel
PY  - 2025
TI  - Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021
JF  - Scientific Reports
VL  - 15
IS  - 1
SP  - 8346
EP  - 8346
PB  - Nature Research
SN  - 20452322
KW  - Tick-borne encephalitis
KW  - TBE
KW  - TBEV
KW  - Orthoflavivirus
KW  - Prevalence
KW  - Incidence
KW  - Asymptomatic
KW  - Abortive
UR  - https://www.nature.com/articles/s41598-025-92560-1
N2  - Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconversions in unvaccinated individuals were confirmed by seroneutralization testing. Questionnaire data were used to determine vaccination status and risk factors. TBEV E protein-specific IgG prevalence was 72.1% (95% CI 68.2–75.7%) in TBEV-vaccinated and 6% (95% CI 4.4–7.8%) in unvaccinated individuals. The estimated annual incidence of infection was 735/100,000. Age was the only factor significantly associated with seroprevalence. The seroreversion rate in unvaccinated individuals was 30.3% within one year, which is almost ten times higher than in vaccinated individuals (3.4%, annual decline rate 8.0%). NS1-specific IgG antibodies were six times more common in vaccinated than unvaccinated HCWs. In conclusion, undetected TBEV infections are common, and infection incidence is much higher than reported clinical cases. Individuals with abortive infections have high antibody decline and seroreversion rates. Whether lifelong protection is conferred and by which immune subsets remain unclear.
ER  -

BRECHET, Arthur; Philipp KOHLER; Tamara DORR; Fabian GRASSLI; Michael VOCK; Jiří SALÁT; Daniel RŮŽEK; Andree FRIEDL; Danielle VUICHARD-GYSIN; Antony CROXATTO; Reto LIENHARD a Rahel ACKERMANN-GAUMANN. Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021. \textit{Scientific Reports}. Berlin: Nature Research, 2025, roč.~15, č.~1, s.~8346-8358. ISSN~2045-2322. Dostupné z: https://doi.org/10.1038/s41598-025-92560-1.

Přehled o publikaci